Table 2.
Bacterial Strain | MIC or Others | Year | Reference |
---|---|---|---|
Mycobacterium tuberculosis H37Rv ATCC 27294 | 12.25 µg/mL | 2010 | [16] |
Isoniazid resistant Mycobacterium tuberculosis | 1.56 µg/mL | 2010 | [16] |
Rifampicin resistant Mycobacterium tuberculosis | 12.5 µg/mL | 2010 | [16] |
Streptomycin resistant Mycobacterium tuberculosis | 6.25 µg/mL | 2010 | [16] |
Mycobacterium fortuitum ATCC 35931 | 50 µg/mL | 2010 | [16] |
Mycobacterium chelonae ATCC 946 | 25 µg/mL | 2010 | [16] |
Mycobacterium kansasii ATCC 12478 | 12.5 µg/mL | 2010 | [16] |
Mycobacterium avium | 100 µg/mL | 2010 | [16] |
Staphylococcus aureus ATCC 25923 | 6.2 µg/mL | 2009 | [58] |
Pneumococcus | 12.5 µg/mL | 2009 | [58] |
Pseudomonas aeruginosa | / | 2009 | [58] |
Bacillus coli ATCC 35218 | / | 2009 | [58] |
Bacillus subtilis | 8 μg/mL | 2011 | [63] |
Bacillus cereus | 8 μg/mL | 2011 | [63] |
Staphylococcus aureus | 31 μg/mL | 2011 | [63] |
Escherichia coli | 31 μg/mL | 2011 | [63] |
Propionibacterium acnes FR 024/12-10 | 1 μg/mL | 2007 | [65] |
Propionibacterium acnes | 2 μg/mL | 1995 | [66] |
Methicillin-susceptible Staphylococcus aureus | 2–>16 μg/mL | 1995 | [66] |
Methicillin-resistant, mupirocin-susceptible Staphylococcus aureus | 4–16 μg/mL | 1995 | [66] |
Methicillin-resistant, mupirocin-resistant Staphylococcus aureus | 4–16 μg/mL | 1995 | [66] |
Mycobacterium aurum | 32 μg/mL | 1998 | [67] |
Bacillus subtilis 78A | NA | 2018 | [68] * |
Pseudomonas fluorescens BKM CR-330 | NA | 2018 | [68] * |
Aspergillus flavus | NA | 2000 | [69] |
Aspergillus niger | NA | 2000 | [69] |
Blue mould | NA | 2000 | [69] |
Rhizopus | NA | 2000 | [69] |
Bacillus subtilis | NA | 2000 | [69] |
Bacillus coli | NA | 2000 | [69] |
Staphylococcus albus | NA | 2000 | [69] |
Lactobacilli | NA | 2000 | [69] |
Baker’s yeast | NA | 2000 | [69] |
Rhodotorula | NA | 2000 | [69] |
Staphylococcus aureus MTCC-96 | 25 μg/mL | 2012 | [70] |
Methicillin-resistant Staphylococcus aureus | 25–50 μg/mL | 2012 | [70] |
Escherichia coli | 20 μg/mL | 2014 | [71] |
Vibrio harveyi | 20 μg/mL | 2014 | [71] |
Bacillus subtilis | 0.5 μg/mL | 2014 | [71] |
Staphylococcus aureus | 1.0 μg/mL | 2014 | [71] |
Mycobacterium abscessus ATCC 19977 | 18.15 µM | 2018 | [72] |
Mycobacterium abscessus subsp. Abscessus AT 07 | 9.07 µM | 2018 | [72] |
Mycobacterium abscessus subsp. Abscessus AT 46 | 9.07 µM | 2018 | [72] |
Mycobacterium abscessus subsp. bolletii AT 52 | 9.07 µM | 2018 | [72] |
Methicillin-resistant Staphylococcus aureus ATCC 43300, AQ 004, AQ 006, AQ 007, AQ 012 | 1–8 μg/mL | 2012 | [73] |
Herpes simplex type 1 virus | 7.5 μg per disc leads to over 4 mm inhibite zone | 1999 | [76] |
Polio type 1 virus | 30 μg per disc leads to over 4 mm inhibite zone | 1999 | [76] |
Human immunodeficiency virus RF | / | NA | [77] |
H1N1 influenza virus pdm09 | ED50: 51.7 μM | 2012 | [22] |
SARS-CoV-2 original strain | IC50: 7.99 μM | 2022 | [79] |
SARS-CoV-2 alpha variant (UK, B.1.1.7) | IC50: 6.05 μM | 2022 | [79] |
SARS-CoV-2 beta variant (South Africa, B.1.351) | IC50: 2.92 μM | 2022 | [79] |
SARS-CoV-2 delta variant (India, B.1.617.2) | IC50: 7.17 μM | 2022 | [79] |
*: U. barbata dry extracts (in terms of usnic acid) 0.24–0.6 mg/mL; NA: Not Available.